19,200 Shares in Lantheus Holdings, Inc. $LNTH Bought by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 19,200 shares of the medical equipment provider’s stock, valued at approximately $1,456,000.

Other hedge funds also recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in Lantheus during the 3rd quarter valued at approximately $1,847,000. Heron Bay Capital Management bought a new position in Lantheus in the 3rd quarter worth approximately $861,000. WINTON GROUP Ltd increased its position in Lantheus by 350.8% in the 3rd quarter. WINTON GROUP Ltd now owns 65,125 shares of the medical equipment provider’s stock worth $3,340,000 after buying an additional 50,677 shares during the period. CWA Asset Management Group LLC bought a new position in Lantheus in the 4th quarter worth approximately $1,670,000. Finally, Elo Mutual Pension Insurance Co acquired a new position in shares of Lantheus during the third quarter worth approximately $942,000. 99.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on LNTH shares. Weiss Ratings restated a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Truist Financial reissued a “buy” rating and issued a $115.00 price target (up from $98.00) on shares of Lantheus in a report on Monday, May 11th. B. Riley Financial restated a “buy” rating on shares of Lantheus in a research report on Friday, May 1st. Finally, William Blair restated an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $101.86.

Lantheus Price Performance

Shares of LNTH stock opened at $109.89 on Friday. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $111.86. The company has a market capitalization of $7.15 billion, a P/E ratio of 26.48 and a beta of -0.06. The stock has a 50 day moving average of $98.00 and a two-hundred day moving average of $81.32. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. The business had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.Lantheus’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities analysts expect that Lantheus Holdings, Inc. will post 4.49 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.